Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism
Language English Country England, Great Britain Media print-electronic
Document type Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
25271250
DOI
10.1177/1470320314549220
PII: 1470320314549220
Knihovny.cz E-resources
- Keywords
- Primary aldosteronism, adrenalectomy, echocardiography, hypertension, left ventricle hypertrophy,
- MeSH
- Adrenalectomy * MeSH
- Antihypertensive Agents pharmacology therapeutic use MeSH
- Time Factors MeSH
- Electrocardiography MeSH
- Hyperaldosteronism complications drug therapy physiopathology surgery MeSH
- Hypertrophy, Left Ventricular complications drug therapy physiopathology surgery MeSH
- Blood Pressure * drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Prevalence MeSH
- Spironolactone pharmacology therapeutic use MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Antihypertensive Agents MeSH
- Spironolactone MeSH
INTRODUCTION: Primary aldosteronism (PA) represents the most common cause of secondary hypertension. Beyond increased blood pressure, additional harmful effects of aldosterone excess including inappropriate left ventricle (LV) hypertrophy were found. We evaluated the effect of adrenalectomy and spironolactone on blood pressure and myocardial remodelling in a long-term follow-up study. METHODS: Thirty-one patients with PA were recruited. Fifteen patients with confirmed aldosterone-producing adenoma underwent adrenalectomy; in the remaining 16 patients, treatment with spironolactone was initiated. Laboratory data, 24-hour ambulatory blood pressure monitoring (ABPM) and echocardiography parameters were evaluated at baseline and at a median follow-up of 64 months. RESULTS: Both approaches reduced blood pressure (p = 0.001 vs. baseline). In both groups we observed a decrease in end-diastolic (p = 0.04, p = 0.01) and end-systolic LV cavity diameters (p = 0.03, p = 0.01). Interventricular septum and posterior wall thickness reduction was significant only after adrenalectomy (p = 0.01, p = 0.03) as was reduction of LV mass index (p = 0.004). A trend to lower LV mass on spironolactone was caused predominantly by diminution of the LV cavity, which was reflected in increased relative wall thickness (p = 0.05). CONCLUSIONS: Although both surgical and conservative treatment can induce a long-term decrease of blood pressure, adrenalectomy seems to be more effective in reduction of LV mass, as it reverses both wall thickening and enlargement of the LV cavity.
References provided by Crossref.org
Should All Patients with Resistant Hypertension Receive Spironolactone?